Barclays
LRMR icon

Barclays’s Larimar Therapeutics LRMR Stock Holding History

Barclays’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$73.7K Sell
16,373
-62,097
-79% -$248K ﹤0.01% 4155
2025
Q4 		$299K Buy
78,470
+7,577
+11% +$29.5K ﹤0.01% 4127
2025
Q3 		$229K Sell
70,893
-13,967
-16% -$52.4K ﹤0.01% 4240
2025
Q2 		$245K Buy
84,860
+30,601
+56% +$70.8K ﹤0.01% 4154
2025
Q1 		$117K Sell
54,259
-16,166
-23% -$51.1K ﹤0.01% 4347
2024
Q4 		$273K Buy
70,425
+10,393
+17% +$68.6K ﹤0.01% 4156
2024
Q3 		$393K Buy
60,032
+45,781
+321% +$368K ﹤0.01% 3920
2024
Q2 		$103K Sell
14,251
-3,953
-22% -$30.3K ﹤0.01% 3888
2024
Q1 		$138K Sell
18,204
-17,087
-48% -$133K ﹤0.01% 4306
2023
Q4 		$161K Buy
35,291
+30,261
+602% +$102K ﹤0.01% 4503
2023
Q3 		$19.9K Sell
5,030
-49,202
-91% -$186K ﹤0.01% 4182
2023
Q2 		$170K Buy
54,232
+25,939
+92% +$106K ﹤0.01% 3326
2023
Q1 		$128K Buy
+28,293
New +$148K ﹤0.01% 4049
2020
Q1 		– Sell
-20
Closed – – 6332
2019
Q4 		$0 Sell
20
-36
-64% -$344 ﹤0.01% 6611
2019
Q3 		$0 Buy
56
+19
+51% +$208 ﹤0.01% 6950
2019
Q2 		$1K Sell
37
-714
-95% -$19K ﹤0.01% 6846
2019
Q1 		$25K Buy
751
+599
+394% +$30.7K ﹤0.01% 6266
2018
Q4 		$9K Sell
152
-801
-84% -$79.1K ﹤0.01% 6218
2018
Q3 		$134K Buy
953
+812
+576% +$98.6K ﹤0.01% 5315
2018
Q2 		$17K Sell
141
-1,599
-92% -$136K ﹤0.01% 6271
2018
Q1 		$155K Buy
1,740
+1,739
+173,900% +$147K ﹤0.01% 5052
2017
Q4 		$0 Hold
1
– – ﹤0.01% 7019
2017
Q3 		$0 Sell
1
-5,088
-100% -$212K ﹤0.01% 6958
2017
Q2 		$214K Buy
5,089
+4,094
+411% +$209K ﹤0.01% 4305
2017
Q1 		$56K Buy
995
+451
+83% +$22.4K ﹤0.01% 5276
2016
Q4 		$20K Buy
544
+532
+4,433% +$21.6K ﹤0.01% 5617
2016
Q3 		$0 Sell
12
-17
-59% -$772 ﹤0.01% 6712
2016
Q2 		$2K Buy
29
+17
+142% +$1.34K ﹤0.01% 5962
2016
Q1 		$1K Sell
12
-700
-98% -$55.3K ﹤0.01% 5976
2015
Q4 		$52K Buy
712
+102
+17% +$16.4K ﹤0.01% 4767
2015
Q3 		$227K Buy
610
+579
+1,868% +$261K ﹤0.01% 4050
2015
Q2 		$13K Sell
31
-18
-37% -$7.53K ﹤0.01% 5942
2015
Q1 		$22K Buy
49
+2
+4% +$949 ﹤0.01% 5777
2014
Q4 		$17K Buy
+47
New +$12.1K ﹤0.01% 6405

Other funds holding LRMR

DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ACM
AIGH Capital Management Baltimore, Maryland $1.59B AUM 855.46% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Barclays's LRMR Position: Q1 2026 in Review

Barclays reduced its Larimar Therapeutics (LRMR) stake by 79% in Q1 2026, selling an estimated $248K and leaving 16,373 shares worth $73.7K. The position accounts for ﹤0.01% of the portfolio, ranked #4155.

Barclays first reported a position in LRMR in Q4 2014 and has held it in 34 quarters since. The position peaked at $393K in Q3 2024. 162 funds tracked by Wall St. Rank hold LRMR as of Q1 2026.

  • Barclays held 16,373 shares of Larimar Therapeutics worth $73.7K as of Q1 2026.
  • Barclays sold 62,097 Larimar Therapeutics shares in Q1 2026, an estimated $248K.
  • Larimar Therapeutics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #4155 holding.
  • Barclays first reported a position in Larimar Therapeutics in Q4 2014 and has held it in 34 quarters since.
  • Barclays's Larimar Therapeutics position peaked at $393K in Q3 2024.
  • 162 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2026.

Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.